慢性丙型肝炎及其抗病毒治疗进展  

Advances in antiviral therapy for chronic hepatitis C

作　　者：卓宏[1] 王涛[1] 谢松梅[1] 陈颖[1] 

机构地区：[1]国家食品药品监督管理总局药品审评中心,北京100038

出　　处：《中国新药杂志》2015年第19期2209-2213,共5页Chinese Journal of New Drugs

摘　　要：自20世纪70年代提出了输血后非甲非乙型肝炎之后直至1989年才应用现代分子克隆技术鉴定出丙型肝炎病毒(HCV),并证实HCV是输血后肝炎的主要致病因子。相对乙型肝炎,丙型肝炎更容易慢性化,导致肝硬化和肝细胞肝癌,治疗更困难,至今尚无有效疫苗预防。因此丙型肝炎是世界主要公共卫生问题之一。随着对丙肝病毒研究及认识的加深,目前抗丙肝病毒药物的研发进入了突破阶段,已经有多个新机制的药物获准上市,还有较多的新药进入了临床试验阶段。本文对丙肝流行病学、治疗学进行了回顾,对新药研发及目前上市的新药进行了归纳。Non-A,non-B post-transfusion hepatitis was proposed in the 1970 s,but until 1989,hepatitis C virus（ HCV） was identified and confirmed as the main pathogenic factor of post transfusion hepatitis by application of modern molecular cloning technologies. Compared with hepatitis B,hepatitis C is not only liable to become chronical and,easier to progress to cirrhosis and hepatocellular carcinoma（ HCC）,but also more difficult to treat. Moreover,there is no effective vaccine for HCV. Therefore,hepatitis C is one of the major public health problems in the world. With the advancing of research and understanding of hepatitis C virus,the research and development of drugs directly agaist HCV are currently close to a breakthrough. At present,many new drugs with multiple mechanisms have been approved,and more and more others candidates are entering clinical trials. This article reviews the epidemiology and therapy about HCV,and offers information on drugs currently under investigation and drugs already on the market.

关 键 词：慢性丙型病毒性肝炎 丙型肝炎病毒 抗病毒治疗 药物研发 

分 类 号：R978.7[医药卫生—药品]